Clinical trials: Severe Pneumonia
COVID-19
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai
This study is to clarify the clinical characteristics of severe and critical COVID-19 from March 1st ,2022 to June 9th, 2022 in Shanghai and to explore the relationship between the characteristics and prognosis in these patients.
- Trial name
- NCT05422963
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Severe Community-Acquired Pneumonia (sCAP), Elderly Infection
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients
The ESCAPE 10 study is a multinational, retrospective, observational cohort study that aims to investigate the epidemiology and outcome determinants of severe community-acquired pneumonia (sCAP) in elderly patients (≥65 years).
- Conditions
- Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation
- Trial name
- ESCAPE10 (NCT07070284)
- Where
- 18 sites in Croatia, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Joan Sabater-Riera
Influenza, Human, SARS Virus
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
Background: Each Belgian winter season is characterized by a wave of influenza like and respiratory symptoms. Especially, the elderly people are more vulnerable to be infected by influenza, but also RSV.
- Conditions
- Influenza, Human, SARS Virus, COVID-19, Espiratory Tract Infections
- Trial name
- PICOV (NCT04527614)
- Testing
- qRT-PCR and serology
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sciensano
Coronavirus Infection, Africa
Important Data on COVID-19 Profile in Africa
The purpose of this study is to Understand the natural history of Coronavirus 2019 (COVID-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of COVID-19 blood and mucosal…
- Trial name
- AIDCO (NCT04847817)
- Where
- 2 sites in Gabon
- Volunteers
- 574 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
COVID-19
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
COVID-19 associated mortality remains high despite the advances in therapeutics such as dexamethasone. The severity of COVID-19 results from direct viral cytotoxicity, and the inflammatory response, which is associated with a…
- Trial name
- EPIC (NCT05182515)
- Testing
- Therapeutic plasma exchange
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
Coronavirus Infection, COVID
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus Infection, COVID, SARS-CoV 2, Respiratory Failure
- Trial name
- CYCOV-II (NCT04385771)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Dr. Alexander Supady
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Community Aquired Pneumonia
Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)
Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by…
- Trial name
- NCT00308659
- Testing
- FOB protected distal microbiological samplings
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19.
- Trial name
- NCT04351659
- Testing
- Blood donation from convalescent donor
- Where
- 2 sites in Singapore
- Volunteers
- 8 people
- Sponsor
- KK Women's and Children's Hospital
COVID-19
Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses
The main objectives are: To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. To identify variables associated to higher risk of bleeding.
- Trial name
- BLEEDING (NCT04380779)
- Where
- Spain
- Volunteers
- 2,430 people
- Sponsor
- Manuel Monreal
COVID-19, Antibody COVID-19
The Role of Obesity in Severe COVID-19 Pathophysiology
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide.
- Trial name
- SAMO (NCT06968442)
- Testing
- Venipuncture
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Franciscus Gasthuis
Severe Pneumonia
Research on the Treatment of Severe Community-acquired Pneumonia in Children
The need for glucocorticoid therapy in children with severe community-acquired pneumonia in the acute phase of the disease remains unclear.
- Trial name
- NCT05768204
- Testing
- Prednisolone Acetate
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Baoping XU
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Covid19, Vitamin D Deficiency
High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study
The world is currently facing a pandemic with the coronavirus (SARS-CoV-2) which leads to the disease of COVID-19. Risk factors for a poor outcome of COVID-19 have so far been identified as older age and co-morbidity including…
- Conditions
- Covid19, Vitamin D Deficiency, Corona Virus Infection, ARDS
- Trial name
- VitCov (NCT04525820)
- Testing
- Single high dose vitamin D, Treatment as usual vitamin D
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Prof. Dr. Jörg Leuppi
SARS CoV 2 Infection, Alveolar; Injury
The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19
COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the…
- Conditions
- SARS CoV 2 Infection, Alveolar; Injury, Children, Pneumonia, Viral
- Trial name
- NCT05619640
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Haseki Training and Research Hospital
Pneumonia
Effect of High Dose Intravenous Vitamin C in Severe Pneumonia
This trial is a multicenter, randomized, double-blind, two-arm, parallel-group, placebo-controlled trial to investigate the effect of high dose intravenous (IV) Vitamin C as an adjunct to the standard of care for patients with…
- Trial name
- VICSEP (NCT05842382)
- Testing
- Active Ingredient
- Where
- 3 sites in Malaysia
- Volunteers
- 484 people
- Sponsor
- Clinical Research Centre, Malaysia
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Severe COVID-19
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients
- Trial name
- NCT04713176
- Testing
- DWJ1248 with Remdesivir
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.